<!-- canonical: https://www.trendhunter.com/trends/OpenAI-Select-Partner -->
<!-- robots: noindex -->

# Clinical Pre-Screening Features
Massive Bio Was Named an OpenAI Select Partner for Oncology AI

By Adam Harrie | Written with AI assistance | Published 2026-08-14 | Tech
Source: Trend Hunter, https://www.trendhunter.com/trends/OpenAI-Select-Partner
References: [mobihealthnews](https://www.mobihealthnews.com/news/massive-bio-named-openai-select-partner-oncology-ai) & [businesswire](https://www.businesswire.com/news/home/20260805332425/en/Massive-Bio-Named-an-OpenAI-Select-Partner)

![Clinical Pre-Screening Features](https://cdn.trendhunterstatic.com/thumbs/627/OpenAI-Select-Partner.jpeg)

Massive Bio was named an OpenAI Select Partner within the OpenAI Partner Network, expanding its work using AI for oncology clinical trial matching and clinical research workflows. The designation gives Massive Bio a formal role within OpenAI’s partner ecosystem as it scales [AI tools for health systems](https://www.trendhunter.com/trends/Clinical-AI-platforms), research networks, biopharmaceutical companies and patient-support organizations.

Massive Bio’s platform uses AI to convert complex clinical trial eligibility criteria into structured, machine-readable parameters and combines [clinical and biomarker data](https://www.trendhunter.com/trends/deepmed-ai) to identify potential trial options for patients. The company plans to expand its OpenAI-related offerings while investing in talent and training, with human oversight and performance evaluation remaining part of its deployment approach.

For clinicians and patients, the partnership could support faster trial identification and reduce manual screening work. It also reflects growing use of generative AI to streamline complex oncology research and patient-access workflows.

Image Credit: Massive Bio

## Trend Insights (Trend Hunter)

- Score: 4.8/10
- Popularity: 16% | Activity: 38% | Freshness: 91%
- Audience gender: 50% men, 50% women
- Primary generations: Millennial, Gen X
- Top markets: North America, Europe

## Categories

[Trend Hunter](https://www.trendhunter.com/trends) > [Tech](https://www.trendhunter.com/tech) > [AI](https://www.trendhunter.com/ai)

## Key Themes

### Why This Trend Is Growing

- **AI Trial Matching:** Generative AI platforms that translate eligibility criteria into structured data create new openings for faster, more precise patient recruitment across complex oncology studies.
- **Clinical Workflow Automation:** Automated pre-screening tools are reshaping research operations by reducing administrative burden while improving the consistency of trial identification and referral processes.
- **Human-guided Medical AI:** Hybrid deployment models that combine machine intelligence with clinical oversight offer a pathway for safer adoption of advanced decision-support systems in regulated healthcare settings.

### Industries Being Reshaped

- **Oncology Research:** AI-assisted biomarker analysis and eligibility matching are enabling more scalable approaches to connecting cancer patients with relevant investigational therapies.
- **Biopharmaceuticals:** Drug developers gain strategic value from machine-readable trial criteria and improved recruitment pipelines that can shorten enrollment timelines and strengthen study execution.
- **Digital Health:** Clinical AI partnerships are expanding the role of healthcare software platforms as infrastructure for patient access, research coordination and precision medicine workflows.

## Related on Trend Hunter

- [Life Sciences-Focused AI Tools](https://www.trendhunter.com/trends/pharmaceutical-and-life-sciences-sector.md)
- [AI-Powered Drug Discovery Platforms](https://www.trendhunter.com/trends/bio-discovery-ai-platform.md)
- [Hospital Clinical AI Tools](https://www.trendhunter.com/trends/clinical-decision-support-platform.md)
- [Cellular Dataset Partnerships](https://www.trendhunter.com/trends/Relation-Therapeutics.md)
- [AI-Driven Discovery Platforms](https://www.trendhunter.com/trends/Pharma-AI-suite.md)
- [Reciprocal Clinical Trials](https://www.trendhunter.com/trends/massive-bio.md)
- [AI Drug Platforms](https://www.trendhunter.com/trends/insilico-medicine-mmai.md)
- [AI-Driven Drug Discovery Collaborations](https://www.trendhunter.com/trends/drug-discovery.md)
- [AI Clinical Recruitment](https://www.trendhunter.com/trends/AI-clinical-recruitment.md)
